.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers recently explored how Boswellia dalzielii brain enzymes modulation could pave the way for new neuroprotective therapies. Traditional African medicine has long utilized Boswellia dalzielii to manage cognitive and neurological issues. However, the scientific basis for these effects required rigorous in vitro validation. A recent study published in BMC Complementary Medicine and Therapies investigated how different plant parts affect enzymes crucial for maintaining cognitive health.
The study found that the stem bark extract was the most potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). These enzymes break down acetylcholine, a neurotransmitter vital for memory. By inhibiting these enzymes, the extract may help maintain higher acetylcholine levels. Consequently, this mechanism mirrors the action of standard dementia medications. Additionally, the root bark extract showed the strongest inhibition of monoamine oxidase (MAO), which is a key target in managing depression and Parkinson's disease.
Furthermore, the extracts influenced other enzymatic pathways. They inhibited ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) and ecto-5'-nucleotidase. These enzymes regulate purinergic signaling, which plays a role in neuroinflammation and cellular energy balance. The stem bark extract also moderately enhanced Na⁺/K⁺-ATPase activity. This modulation helps maintain the ionic gradients necessary for proper neuronal firing. Overall, the presence of stilbenoids across all plant parts likely contributes to these multi-target effects.
While these results are preliminary, they provide a strong foundation for future research. Specifically, the stem bark's potency suggests it could be a primary candidate for isolating bioactive compounds. The multi-enzyme inhibitory profile indicates that Boswellia dalzielii might offer a holistic approach to complex brain disorders. Future in vivo studies are necessary to confirm if these laboratory findings translate into clinical benefits for patients with Alzheimer's or other cognitive impairments.
According to the study, the stem bark extract demonstrated the most potent inhibition of enzymes related to memory and neuronal function, followed by the root and leaf extracts.
The stem bark extract showed inhibitory potency against cholinesterase enzymes that was comparable to Prostigmine, a standard pharmaceutical inhibitor, in laboratory settings.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study finds that Boswellia dalzielii extracts, particularly the stem bark, inhibit key enzymes like AChE and MAO, suggesting potential neuroprotective use...
6 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
